A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 1, 2009, Pages 33-40

  George, C ^b,c   Yesoda, A ^c   Jayakumar, B ^d   Lal, L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASTERSKILL College of Nursing & Health   (Malaysia)

^c GOVERNMENT MEDICAL COLLEGE   (India)

^d Medical College Hospital Thiruvananthapuram   (India)

Author keywords

Clinical outcomes; Cost of HIV treatment; Drug utilization; HAART regimen; Pharmacy practice

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DROWSINESS; DRUG COST; DRUG UTILIZATION; EDEMA; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INSOMNIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OPTIC NEURITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PIGMENTATION; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, TEACHING; HUMANS; INDIA; LAMIVUDINE; MALE; MEDICATION ADHERENCE; NEVIRAPINE; PROSPECTIVE STUDIES; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 58149288047     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00988.x     Document Type: Article

References (46)

1. Fletcher V, Kakuda NK, Collier AC (2002) Human immunodeficiency virus infection. In : Dipiro TJ, Tallbert LR, Yee CG, Matzke RG, Wells GB, Posey LM, eds. Pharmacotherapy : a pathophysiological approach, 5th edn. United States of America : McGraw -Hill Medical Publishing Division, 2151 2174.
2. National AIDS Control Organization, India (2005) Basic epidemiology and natural history of HIV/AIDS Specialist's training and reference module. India : National AIDS Control Organization, 3 29.
3. AIDS Education and Research Trust (AVERT). World estimate of the HIV/AIDS epidemic at the end of 2004. Available at: http://www.avert.org/worldstats.htm (accessed 21 March 2008).
4. National AIDS Control Organization (NACO). Facts & figures. HIV estimation 2005. Available at: http://www.nacoonline.org/Quick_Links/HIV_Data/ (accessed 21 March 2008).
5. National AIDS Control Organization (2003-2006) HIV fact sheets: based on HIV Sentinel surveillance data in India. Available at: http://www.nacoonline. org/HIV_Fact_Sheet_2006.pdf (accessed 25 September 2008).
6. National AIDS Control Organization (2006) HIV Sentinel surveillance and HIV estimation. Available at: http://www.nacoonline.org/Quick_Links/HIV_Data (accessed 25 September 2008).
7. Ryser HJ-P, Fluckiger R (2005) Keynote review: progress in targeting HIV-1 entry. Drug Discovery Today, 10, 1085 1094.
8. U.S. Food and Drug Administration - Center for Drug Evaluation and Research. Approval of FDA regulated products. Available at: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed March 21 2008).
9. Palella FJ, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853 860.
10. Detels R, Munoz A, McFarlane G et al. (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. AIDS Cohort Study Investigators. JAMA, 280, 1497 1503.
11. Kitahata MM, Koepsell TD, Deyo RA et al. (1996) Physician's experience with the acquired immunodeficiency syndrome as a factor in patient's survival. New England Journal of Medicine, 334, 701 716.
12. Lucas GM, Chaisson RE, Moore RD (1999) Highly active antiretroviral therapy in a large urban clinic risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81 87.
13. Finzi D, Blankson J, Siliciano JD et al. (1999) Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine, 5, 512 517.
14. Wong JK, Hezareh M, Gunthard HF et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 278, 1291 1295.
15. Mellors JW, Muñoz A, Giorgi JV et al. (1997) Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 126, 946 954.
16. Bangsberg DR, Moss AR, Deeks SG (2004) Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 53, 696 699.
17. Harrigan PR, Hogg RS, Dong WW et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. Journal of Infectious Diseases, 191, 339 347.
18. Bangsberg DR, Perry S, Charlebois ED et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15, 1181 1183.
19. Rehle TM, Shisana O (2003) Epidemiological and demographic HIV/AIDS projections:South Africa. African Journal of AIDS Research, 2, 1 8.
20. Campsmith LM, Nakashima AK, Davidson AJ (2003) Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project. Health and Quality of Life Outcomes, 1, 1 12.
21. Pfutzner A, Dietrich U, Eichel VU et al. (1992) HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype [Abstract]. Journal of Acquired Immune Deficiency Syndromes, 5, 972 977. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1453326 (accessed 21 March 2008).
22. Solomon S, Kumarasamy N, Ganesh AK et al. (1998) Prevalence and risk factors of HIV-1 and HIV-2 infection in urban and rural areas in Tamil Nadu, India. International Journal of STD and AIDS, 9, 98 103.
23. Ousmane MD, Gilles P, Ibrahima D et al. (2000) Incidence of HIV-1 and HIV-2 infections in a rural community in southern Senegal. AIDS, 14, 1671 1672.
24. Pal BB, Khuntia HK, Acharya AS et al. (2003) Drug abusers - a new high risk population for HIV infection in Orissa. Indian Journal of Medical Microbiology, 21, 262 264.
25. Robbins GK, Gruttola VD, Shafer RW et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine, 349, 2293 2303.
26. Laurent C, Kouanfack C, Shiro SK et al. (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet, 364, 29 34.
27. Leth FV, Phanuphak P, Ruxrungtham K et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet, 363, 1253 1263.
28. Squires KE, Gulick R, Tebas P et al. (2000) A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS, 14, 1591 1600.
29. Gulick RM, Ribaudo HJ, Shikuma CM et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New England Journal of Medicine, 350, 1850 1861.
30. Elena F, Santamariña E, Domingo P et al. (2004) Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or less. AIDS, 18, 1727 1729.
31. Coetzee D, Boulle A, Hildebrand K et al. (2004) Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS, 18, S27 S31.
32. Joly V, Flandre P, Meiffredy V et al. (2002) Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficency virus - infected nucleoside- experienced patients with no prior exposure to lamividine, stavudine or protease inhibitors (Novavir Trial). Antimicrobial Agents and Chemotherapy, 46, 1906 1913.
33. Zaheer MS, Rabbani MU, Ahmad Z et al. (2003) Clinical and demographic profile of patients of aids in and around Aligarh. JIACM, 4, 121 126.
34. Bangsberg DR, Edwin D, Charlebois ED et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17, 1925 1932.
35. Sethi AK, Celentano DD, Gange SJ et al. (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases, 37, 1112 1118.
36. 9 cells/L. HIV Treatment Bulletin, 139, 810 816.
37. Mannheimer SB, Matts J, Telzak E et al. (2005) Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS CARE, 17, 10 22.
38. Mohammed H, Kieltyka I, Alston GR et al. (2004) Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDs, 18, 289 296.
39. Lanièce I, Ciss M, Desclaux A et al. (2003) Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS, 17, S103 S109.
40. Wagner G, Miller LG, Rand MS (2004) Is the influence of social desirability on patient's self-reported adherence overrated. Journal of Acquired Immune Deficiency Syndrome, 35, 203 204.
41. Kumarasamy N, Solomon S, Chaguturu SK et al. (2003) The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India (Research Letters). AIDS, 17, 2267 2269.
42. Pujari S, Naik E, Patel A et al. (2002) Safety, tolerability, and efficacy of nevirapine-based HAART amongst antiretroviral naïve HIV-1-infected patients in India. Session 65 Poster Session. 9th conference on retroviruses and opportunistic infections, February 24-28, Seattle, WA.
43. Antiviral drugs (2005). Monthly Index of Medical Specialties. (MIMS). New Delhi, India : A.E. Morgan Publications (India) Private Limited.
44. Antiviral drugs (2005). Current Index of Medical Specialties. (CIMS). Bangalore, India : CPM Medica.
45. World Bank Group. India data profile. Available at: http://devdata. worldbank.org/external/CPProfile.asp?PTYPE=CP&CCODE=IND (accessed 21 March 2008).
46. Reserve Bank of India RBI reference rate. Available at: http://www.rbi.org.in/home.aspx# (accessed March 21 2008).